Brief: Foghorn Therapeutics Announces First Patient Dosed With FHD-909 In A Phase 1 Trial For SMARCA4 Mutated Solid Tumors
10/10/2024 12:05
Oct 10 (Reuters) - Foghorn Therapeutics Inc. FHTX.O :
* FOGHORN THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED WITH
FIRST-IN-CLASS ORAL SMARCA2 SELECTIVE INHIBITOR FHD-909 IN A
PHASE 1 TRIAL FOR SMARCA4 MUTATED SOLID TUMORS
Source text for Eikon: ID:nGNX5qm5st
Further company coverage: FHTX.O
((Reuters.Briefs@thomsonreuters.com;))